These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35344464)

  • 1. Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.
    Ong-Lim AL; Shukarev G; Trinidad-Aseron M; Caparas-Yu D; Greijer A; Duchene M; Scheper G; van Paassen V; Le Gars M; Cahill CP; Schuitemaker H; Douoguih M; Jacquet JM
    Hum Vaccin Immunother; 2022 Nov; 18(5):2044255. PubMed ID: 35344464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.
    Leroux-Roels I; Leroux-Roels G; Shukarev G; Schuitemaker H; Cahill C; de Rooij R; Struijs M; van Zeeburg H; Jacquet JM
    Hum Vaccin Immunother; 2021 May; 17(5):1366-1373. PubMed ID: 33175637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
    Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
    Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
    Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
    Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
    Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X
    Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
    Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial.
    Zheng Y; Ying Z; Zou Y; Zhu T; Qian D; Han W; Jiang Y; Jiang Z; Li X; Wang J; Lei J; Xu L; Jiang D; Li C; Liu X
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
    Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
    Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of a New Inactivated Polio Vaccine Made From Sabin Strains: A Randomized, Double-Blind, Active-Controlled, Phase 2/3 Seamless Study.
    Capeding MR; Gomez-Go GD; Oberdorfer P; Borja-Tabora C; Bravo L; Carlos J; Tangsathapornpong A; Uppala R; Laoprasopwattana K; Yang Y; Han S; Wittawatmongkol O
    J Infect Dis; 2022 Aug; 226(2):308-318. PubMed ID: 33351072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
    Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
    Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
    Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines.
    Sun G; Wang G; Zhong H
    Inflammopharmacology; 2024 Apr; 32(2):1025-1038. PubMed ID: 38308795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.
    Yan S; Chen H; Zhang Z; Chang S; Xiao Y; Luo L; Zhang Z; Sun L; Chen X; Yang Y; Shi X; Guo Y; Sun Y; Li H; Li N; Han S; Ma M; Yang X
    Vaccine; 2020 Sep; 38(40):6274-6279. PubMed ID: 32747216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study.
    Chu K; Li Y; Yu D; Song Y; Liu S; Xue F; Shan Y; Meng W; Pan H
    Vaccine; 2023 May; 41(22):3467-3471. PubMed ID: 37127526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
    Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
    J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
    Hotta C; Ogawa T; Shirasawa H
    Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China.
    Guo S; Li Z; Zheng M; Wu F; Sun J; Tuo L; Li S; Li X; Wei L; Xia Z; Xie P; Chen X; Zhao Y; Gao Y; Yu D
    Vaccine; 2024 Aug; 42(21):126183. PubMed ID: 39088987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey.
    Xu J; Wang Q; Kuang S; Rong R; Zhang Y; Fu X; Tang W
    Hum Vaccin Immunother; 2021 Jul; 17(7):2125-2131. PubMed ID: 33759702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses.
    Chu K; Han W; Jiang D; Jiang Z; Zhu T; Xu W; Hu Y; Zeng G
    Expert Rev Vaccines; 2021 Jun; 20(6):761-767. PubMed ID: 33861679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.